<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149691_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152631</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHEH2012US025246</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121221</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHEH2012US025246</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Bennett</reportergivename>
			<reporterfamilyname>Myers</reporterfamilyname>
			<reporterstreet>3980 Sheridan Dr. Suite 200</reporterstreet>
			<reportercity>Amherst</reportercity>
			<reporterstate>NY</reporterstate>
			<reporterpostcode>14226</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>SB</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19560715</patientbirthdate>
			<patientweight>61.224</patientweight>
			<patientheight>163</patientheight>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Myopathy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Insomnia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Arthralgia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pelvic pain</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pain in extremity</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Back pain</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Malaise</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Fatigue</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Amnesia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Anxiety</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Patient became hypotensive / diastolic blood pressure was 65</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypotensive</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypotension</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121221</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Dizziness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dizziness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dizziness</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121221</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Leg pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Leg pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pain in extremity</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121221</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Medication is not working</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug ineffective</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121221</testdate>
				<testname>Blood pressure diastolic</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121221</testdate>
				<testname>Heart rate</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.5 mg, QD</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121221</drugstartdate>
				<actiondrug>4</actiondrug>
				<drugadditional>ExpDT=31-MAR-2013</drugadditional>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dizziness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dizziness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain in extremity</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain in extremity</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>COREG</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>6.25</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>6.25 mg, BID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CARVEDILOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>COREG</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>12.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>12.5 mg BID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CARVEDILOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>HYDROCODONE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCODONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>HYDROXYZINE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>25 mg, TID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROXYZINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PROVIGIL</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>200 mg, QD (morning)</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MODAFINIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>100 mg, TID</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ARICEPT</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>10 mg, QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>DONEPEZIL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ARICEPT</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>100 mg, QHS</drugdosagetext>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>DONEPEZIL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CYMBALTA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>120</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>120 mg, QD</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DULOXETINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CYMBALTA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>60</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>60 mg QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DULOXETINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>XANAX</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.5 mg, BID (PRN)</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ALPRAZOLAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>RESTORIL</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>30</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>30 mg, QHS</drugdosagetext>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>TEMAZEPAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>HYDROCHLOROTHIAZIDE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>25 mg, QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ACTHAR</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>80 U/mlPRN</drugdosagetext>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CORTICOTROPIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>NORCO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>325-7.5 mg QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCODONE BITARTRATE, PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>VIT D</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>2000</drugstructuredosagenumb>
				<drugstructuredosageunit>025</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>2000 IU, QD</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ERGOCALCIFEROL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHEH2012US025246, is a combined spontaneous initial report received from a physician via patient oriented program Gilenya support program and patient oriented program Gilenya first dose observation program on 21 Dec 2012 and 22 Dec 2012 and follow-up report received from other healthcare professional via Gilenya support program on 03 Jan 2013 and follow up report received from consumer via Gilenya support program on 04 Jan 2013 and follow up report received from the physician on 18 Jan 2013 and follow up report received from the physician on 22 Jan 2013: This is also a quality complaint report (AQWA: 645542). This report refers to a 56-year-old, non-pregnant, female patient. The patient's medical history included myopathy (unspecified), insomnia, pain in joint, pelvic region and thigh, back pain (postural), other malaise, fatigue and memory loss. The patient's current condition included hypertension and anxiety. The concomitant medication of the patient included Coreg (carvedilol), hydrocodone, hydroxyzine, Provigil (modafinil), Lyrica (pregabalin), Aricept (donepezil hydrochloride), Restoril (temazepam), Cymbalta (duloxetine hydrochloride), Xanax (alprazolam), hydrochlorthiazide, Acthar (corticotropin), Norco (hydrocodone bitartrate, paracetamol) and Vitamin D (ergocalciferol). On 21 Dec 2012, the baseline heart rate (HR) of the patient was 88 bpm (beats per minute) at 12:10 PM. This patient received treatment with Gilenya (fingolimod) (Exp. Date: 31 Mar 2013) on 21 Dec 2012 at 12:30 PM at a dose of 0.5 mg once daily for multiple sclerosis. The physician reported that after the patient had taken the first dose of Gilenya, she became symptomatic. The patient became hypotensive without bradycardia and at that point, it was about five hours into first dose observation (FDO). The patient had a decrease in diastolic blood pressure (BP) to 65 (unit not specified). The patient's minimum HR was 64 bpm during the FDO and it took five hours to reach this value from the first dose of Gilenya. The patient also had leg pain and dizziness. The patient was treated with intravenous (IV) 1000 ml normal saline to get diastolic BP higher but no changes were observed. The patient's MD advised that the patient should go to the ER (emergency room) and have a 23 hour observation period. The patient had an ECG (electrocardiogram) and blood tests (result and date unspecified) done. The patient was admitted to the local hospital and discharged on the same day. The patient further confirmed that she was down to her last 5 pills. The patient also asked how long it would take for the medication to work because it was not working for her. Treatment with Gilenya was ongoing. The physician assessed the events as serious. Outcome of the event hypotension was reported as recovered on the same day and for the other events was not reported. The causality of the events was not reported.

Follow-up report received from other healthcare professional via patient oriented program Gilenya support program on 03 Jan 2013. Reporter and information regarding hospitalization were updated.

Follow up report received from consumer via Gilenya support program on 04 Jan 2013: Information related to new event (medication was not working) was updated.

Follow up report received from the physician on 18 Jan 2013: Information related to medical history, concomitant medications and hospitalization details were updated.

Follow up report received from the physician on 22 Jan 2013: Information regarding current condition, dosage of concomitant medications and details of FDO was updated.</narrativeincludeclinical>
				<sendercomment>Medic Comment: The available reported data does not allow for a proper causality assessment. The case has been conservatively assessed as suspected and will be reassessed after the availability of follow up</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
